A pharmacokinetic binding model for bevacizumab and VEGF(165) in colorectal cancer patients

PURPOSE: To characterize the population pharmacokinetics of bevacizumab, its binding properties to VEGF(165) and the effect of demographic data and VEGF-A polymorphisms on the interplay between bevacizumab serum pharmacokinetics and VEGF(165) serum concentrations in patients with colorectal cancer s...

Descripción completa

Detalles Bibliográficos
Autores principales: Panoilia, Eirini, Schindler, Emilie, Samantas, Epaminontas, Aravantinos, Gerasimos, Kalofonos, Haralabos P., Christodoulou, Christos, Patrinos, George P., Friberg, Lena E., Sivolapenko, Gregory
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer Berlin Heidelberg 2015
Materias:
Original Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4365273/
https://www.ncbi.nlm.nih.gov/pubmed/25687989
http://dx.doi.org/10.1007/s00280-015-2701-3

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4365273/
https://www.ncbi.nlm.nih.gov/pubmed/25687989
http://dx.doi.org/10.1007/s00280-015-2701-3

Ejemplares similares